Daiichi Sankyo in Oncology

Our mission is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.


Priority Areas at Each R&D Stage

At the Daiichi Sankyo Group, we implement research and development initiatives that precisely address unmet medical needs, and defining oncology as a primary focus area, we also aim to create advanced new drugs that revolutionise the standard of care by advancing research and development. 


Dynamic and Sustainable R&D Engine

The oncology portfolio of Daiichi Sankyo is powered by our research engines:

  • Biologics, medicinal chemistry, modality, and other research laboratories in Japan


“3 and Alpha” R&D Strategy

Anchored by our DXd antibody drug conjugate (ADC) technology, our obligation is to harness the power of true innovation to discover and develop innovative first-in-class treatments that transform the standard of care for patients with cancer.


Enhanced Capabilities Through Collaboration

To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology, diagnostics and pipeline prioritisation.

Reports and publications

As a company we work to support physicians and the wider healthcare system in tackling the great healthcare challenges of our time. This includes providing solutions to policy, commissioning and service delivery challenges in the NHS. In this section you will find published reports on policy, public affairs and campaigns which we support in the area of oncology. 

Policy report: Secondary breast cancer and COVID19 recovery plan (October 2021)

DSC/22/0040 - March 2022

back to top